Lutetium-177 PSMA Therapy for Advanced Prostate Cancer
Breakthrough Treatment for Metastatic Prostate Cancer in Europe. Offered in Germany, Turkey, and Israel, this targeted therapy delivers radiation directly to cancer cells while sparing healthy tissues.
Why Choose Lu-177-PSMA Therapy Abroad?
Highly specialized oncology clinics in Germany, Turkey, and Israel
Access to cutting-edge nuclear medicine units
Comprehensive diagnosis and imaging before therapy
Short waiting times and personal medical coordinator support
Option to combine with PSMA PET-CT for precise targeting
How Lu-177-PSMA Therapy Works
This treatment uses a molecule that binds to PSMA (Prostate-Specific Membrane Antigen) — a protein highly expressed in prostate cancer cells. The molecule is combined with radioactive Lutetium-177, which releases beta radiation, destroying cancer cells from the inside.
This therapy is particularly effective in:
- Metastatic castration-resistant prostate cancer (mCRPC)
- PSMA-positive tumors (confirmed via PSMA PET-CT)

Benefits of Lu-177-PSMA Therapy
Improves survival and quality of life
Patients often experience significant improvement in their condition and overall well-being.
Minimal side effects compared to chemotherapy
Targeted nature of the therapy reduces harm to healthy cells, leading to fewer side effects.
Targets cancer precisely
The therapy specifically attacks PSMA-positive cells, ensuring no damage to healthy organs.
Convenient Dosing Schedule
Usually administered as 3–6 cycles every 6–8 weeks, making it manageable for patients.
Get a Free Case Review
We can review your medical documents within 24 hours and connect you with top specialists.